Armata Common Stock Total Equity vs Other Current Liab Analysis

ARMP Stock

USD 2.76 0.10 3.50%

Armata Pharmaceuticals financial indicator trend analysis is way more than just evaluating Armata Pharmaceuticals prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Armata Pharmaceuticals is a good investment. Please check the relationship between Armata Pharmaceuticals Common Stock Total Equity and its Other Current Liab accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Armata Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in population.

To learn how to invest in Armata Stock, please use our How to Invest in Armata Pharmaceuticals guide.

Common Stock Total Equity vs Other Current Liab

Common Stock Total Equity vs Other Current Liab Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Armata Pharmaceuticals Common Stock Total Equity account and Other Current Liab. At this time, the significance of the direction appears to have significant contrarian relationship.

The correlation between Armata Pharmaceuticals' Common Stock Total Equity and Other Current Liab is -0.32. Overlapping area represents the amount of variation of Common Stock Total Equity that can explain the historical movement of Other Current Liab in the same time period over historical financial statements of Armata Pharmaceuticals, assuming nothing else is changed. The correlation between historical values of Armata Pharmaceuticals' Common Stock Total Equity and Other Current Liab is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Common Stock Total Equity of Armata Pharmaceuticals are associated (or correlated) with its Other Current Liab. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Other Current Liab has no effect on the direction of Common Stock Total Equity i.e., Armata Pharmaceuticals' Common Stock Total Equity and Other Current Liab go up and down completely randomly.

Correlation Coefficient

-0.32

Relationship Direction	Negative
Relationship Strength	Insignificant

View All Relationships

Common Stock Total Equity

The total value of common stock equity held by shareholders, representing their ownership interest in the company.

Other Current Liab

Most indicators from Armata Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Armata Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Armata Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in population.

To learn how to invest in Armata Stock, please use our How to Invest in Armata Pharmaceuticals guide.As of 05/09/2024, Enterprise Value is likely to grow to about 234.9 M, while Selling General Administrative is likely to drop slightly above 11.1 M.

Armata Pharmaceuticals fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Cash And Short Term Investments	Common Stock Shares Outstanding	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Short Term Debt	Intangible Assets	Net Debt	Non Currrent Assets Other	Net Receivables	Common Stock Total Equity	Short Term Investments	Common Stock
Total Assets		0.93	0.87	0.87	-0.39	0.97	0.05	0.22	0.62	0.99	0.62	0.96	0.89	0.5	-0.18	0.93	0.97	0.71	0.8	0.31	0.89	-0.27	0.83	-0.23	0.11	-0.23
Short Long Term Debt Total	0.93		0.8	0.78	-0.61	0.94	0.01	0.1	0.42	0.95	0.42	0.9	0.94	0.32	-0.18	0.96	0.94	0.47	0.71	0.17	0.99	0.04	0.88	-0.15	0.02	-0.15
Other Current Liab	0.87	0.8		0.9	-0.26	0.86	0.09	0.03	0.57	0.85	0.57	0.92	0.72	0.48	-0.18	0.78	0.85	0.66	0.85	0.2	0.77	-0.23	0.63	-0.32	0.2	-0.32
Total Current Liabilities	0.87	0.78	0.9		-0.14	0.86	0.08	0.2	0.47	0.86	0.47	0.89	0.65	0.64	-0.14	0.73	0.86	0.67	0.97	0.21	0.75	-0.35	0.66	-0.22	0.12	-0.22
Total Stockholder Equity	-0.39	-0.61	-0.26	-0.14		-0.34	0.33	-0.2	-0.29	-0.41	-0.29	-0.25	-0.76	0.37	-0.11	-0.7	-0.33	-0.06	-0.1	-0.16	-0.59	-0.69	-0.35	0.06	0.03	0.06
Property Plant And Equipment Net	0.97	0.94	0.86	0.86	-0.34		0.16	0.07	0.48	0.98	0.48	0.98	0.85	0.57	-0.27	0.89	1.0	0.63	0.79	0.15	0.93	-0.28	0.92	-0.13	0.02	-0.13
Retained Earnings	0.05	0.01	0.09	0.08	0.33	0.16		-0.44	-0.23	0.06	-0.23	0.19	-0.11	0.54	-0.97	-0.09	0.15	0.05	0.04	-0.37	0.05	-0.32	0.31	0.69	-0.61	0.69
Accounts Payable	0.22	0.1	0.03	0.2	-0.2	0.07	-0.44		0.3	0.2	0.3	0.03	0.24	-0.05	0.42	0.24	0.08	0.25	0.31	0.72	0.08	-0.13	-0.1	-0.36	0.37	-0.36
Cash	0.62	0.42	0.57	0.47	-0.29	0.48	-0.23	0.3		0.52	1.0	0.51	0.58	0.24	0.17	0.59	0.48	0.89	0.4	0.27	0.3	-0.24	0.26	-0.35	0.33	-0.35
Non Current Assets Total	0.99	0.95	0.85	0.86	-0.41	0.98	0.06	0.2	0.52		0.52	0.96	0.9	0.46	-0.19	0.93	0.97	0.61	0.79	0.33	0.93	-0.22	0.85	-0.24	0.11	-0.24
Cash And Short Term Investments	0.62	0.42	0.57	0.47	-0.29	0.48	-0.23	0.3	1.0	0.52		0.51	0.58	0.24	0.17	0.59	0.48	0.89	0.4	0.28	0.31	-0.24	0.27	-0.35	0.33	-0.35
Common Stock Shares Outstanding	0.96	0.9	0.92	0.89	-0.25	0.98	0.19	0.03	0.51	0.96	0.51		0.79	0.57	-0.29	0.84	0.98	0.65	0.81	0.17	0.88	-0.34	0.86	-0.2	0.09	-0.2
Non Current Liabilities Total	0.89	0.94	0.72	0.65	-0.76	0.85	-0.11	0.24	0.58	0.9	0.58	0.79		0.16	-0.08	0.99	0.84	0.52	0.58	0.3	0.91	0.13	0.76	-0.19	0.06	-0.19
Other Current Assets	0.5	0.32	0.48	0.64	0.37	0.57	0.54	-0.05	0.24	0.46	0.24	0.57	0.16		-0.5	0.24	0.58	0.63	0.66	-0.23	0.31	-0.72	0.55	0.36	-0.33	0.36
Other Stockholder Equity	-0.18	-0.18	-0.18	-0.14	-0.11	-0.27	-0.97	0.42	0.17	-0.19	0.17	-0.29	-0.08	-0.5		-0.09	-0.26	-0.06	-0.1	0.33	-0.22	0.18	-0.43	-0.7	0.67	-0.7
Total Liab	0.93	0.96	0.78	0.73	-0.7	0.89	-0.09	0.24	0.59	0.93	0.59	0.84	0.99	0.24	-0.09		0.88	0.57	0.66	0.3	0.93	0.06	0.78	-0.2	0.07	-0.2
Property Plant And Equipment Gross	0.97	0.94	0.85	0.86	-0.33	1.0	0.15	0.08	0.48	0.97	0.48	0.98	0.84	0.58	-0.26	0.88		0.63	0.79	0.15	0.92	-0.3	0.92	-0.14	0.03	-0.14
Total Current Assets	0.71	0.47	0.66	0.67	-0.06	0.63	0.05	0.25	0.89	0.61	0.89	0.65	0.52	0.63	-0.06	0.57	0.63		0.63	0.1	0.38	-0.51	0.44	-0.14	0.19	-0.14
Short Term Debt	0.8	0.71	0.85	0.97	-0.1	0.79	0.04	0.31	0.4	0.79	0.4	0.81	0.58	0.66	-0.1	0.66	0.79	0.63		0.22	0.69	-0.36	0.58	-0.2	0.11	-0.2
Intangible Assets	0.31	0.17	0.2	0.21	-0.16	0.15	-0.37	0.72	0.27	0.33	0.28	0.17	0.3	-0.23	0.33	0.3	0.15	0.1	0.22		0.15	-0.14	-0.09	-0.65	0.5	-0.65
Net Debt	0.89	0.99	0.77	0.75	-0.59	0.93	0.05	0.08	0.3	0.93	0.31	0.88	0.91	0.31	-0.22	0.93	0.92	0.38	0.69	0.15		0.06	0.89	-0.11	-0.02	-0.11
Non Currrent Assets Other	-0.27	0.04	-0.23	-0.35	-0.69	-0.28	-0.32	-0.13	-0.24	-0.22	-0.24	-0.34	0.13	-0.72	0.18	0.06	-0.3	-0.51	-0.36	-0.14	0.06		-0.19	0.08	-0.11	0.08
Net Receivables	0.83	0.88	0.63	0.66	-0.35	0.92	0.31	-0.1	0.26	0.85	0.27	0.86	0.76	0.55	-0.43	0.78	0.92	0.44	0.58	-0.09	0.89	-0.19		0.13	-0.22	0.13
Common Stock Total Equity	-0.23	-0.15	-0.32	-0.22	0.06	-0.13	0.69	-0.36	-0.35	-0.24	-0.35	-0.2	-0.19	0.36	-0.7	-0.2	-0.14	-0.14	-0.2	-0.65	-0.11	0.08	0.13		-0.9	1.0
Short Term Investments	0.11	0.02	0.2	0.12	0.03	0.02	-0.61	0.37	0.33	0.11	0.33	0.09	0.06	-0.33	0.67	0.07	0.03	0.19	0.11	0.5	-0.02	-0.11	-0.22	-0.9		-0.9
Common Stock	-0.23	-0.15	-0.32	-0.22	0.06	-0.13	0.69	-0.36	-0.35	-0.24	-0.35	-0.2	-0.19	0.36	-0.7	-0.2	-0.14	-0.14	-0.2	-0.65	-0.11	0.08	0.13	1.0	-0.9

Click cells to compare fundamentals

Armata Pharmaceuticals Account Relationship Matchups

Armata Pharmaceuticals fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	25.5M	39.5M	69.8M	95.8M	110.0M	115.5M
Other Current Liab	3.0M	3.5M	2.2M	6.2M	5.4M	5.7M
Total Current Liabilities	4.9M	6.7M	4.8M	24.9M	16.5M	17.3M
Total Stockholder Equity	14.6M	18.9M	25.4M	36.1M	(32.1M)	(30.5M)
Property Plant And Equipment Net	4.2M	12.8M	38.1M	46.7M	57.3M	60.1M
Retained Earnings	(157.5M)	(179.7M)	(202.9M)	(239.8M)	(308.8M)	(324.3M)
Accounts Payable	547K	956K	1.1M	1.7M	1.6M	1.3M
Cash	6.0M	9.6M	10.3M	14.9M	13.5M	11.2M
Non Current Assets Total	18.8M	28.7M	54.8M	68.8M	90.8M	95.4M
Cash And Short Term Investments	6.0M	9.6M	10.3M	14.9M	13.5M	11.3M
Common Stock Shares Outstanding	7.8M	16.4M	24.1M	34.3M	36.1M	37.9M
Liabilities And Stockholders Equity	25.5M	39.5M	69.8M	95.8M	110.0M	115.5M
Non Current Liabilities Total	6.0M	14.0M	39.6M	34.9M	125.6M	131.8M
Other Current Assets	622K	1.2M	4.7M	10.3M	2.3M	2.3M
Other Stockholder Equity	172.0M	198.4M	228.0M	275.5M	276.4M	251.6M
Total Liab	10.9M	20.7M	44.4M	59.8M	142.0M	149.1M
Property Plant And Equipment Gross	4.2M	12.8M	48.3M	57.8M	69.1M	72.6M
Total Current Assets	6.7M	10.8M	15.0M	27.0M	19.2M	11.1M
Net Debt	(3.2M)	3.5M	27.7M	34.0M	106.8M	112.2M
Non Currrent Assets Other	836K	(2.1M)	(8.3M)	(9.6M)	2.5M	2.6M
Common Stock Total Equity	99K	187K	271K	361K	324.9K	308.7K
Common Stock	99K	187K	271K	361K	324.9K	308.7K
Capital Surpluse	172.0M	198.4M	228.0M	275.5M	247.9M	245.6M
Property Plant Equipment	4.2M	12.8M	2.2M	3.6M	4.2M	4.4M
Net Tangible Assets	11.1M	15.4M	11.7M	22.3M	25.7M	17.0M
Other Assets	(1K)	23.1M	13.2M	18.6M	21.4M	22.5M
Net Invested Capital	14.6M	19.6M	25.4M	36.1M	50.2M	25.5M
Net Working Capital	1.8M	4.1M	10.2M	2.2M	2.7M	3.5M

Pair Trading with Armata Pharmaceuticals

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Armata Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Armata Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.

Moving against Armata Stock

0.63	ELYM	Eliem Therapeutics	Pair Corr
0.57	VRCA	Verrica Pharmaceuticals Financial Report 14th of May 2024	Pair Corr
0.52	ZURA	Zura Bio Limited Financial Report 10th of May 2024	Pair Corr
0.5	ELDN	Eledon Pharmaceuticals	Pair Corr
0.42	HOOK	Hookipa Pharma	Pair Corr

The ability to find closely correlated positions to Armata Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Armata Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Armata Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Armata Pharmaceuticals to buy it.

The correlation of Armata Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Armata Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Armata Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Armata Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

When determining whether Armata Pharmaceuticals is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if Armata Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Armata Pharmaceuticals Stock. Highlighted below are key reports to facilitate an investment decision about Armata Pharmaceuticals Stock:

How To Invest In Armata

Details

Is Armata Stock a good investment?

Details

What is Armata Pharmaceuticals' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Armata Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in population.

To learn how to invest in Armata Stock, please use our How to Invest in Armata Pharmaceuticals guide.

You can also try the Financial Widgets module to easily integrated Macroaxis content with over 30 different plug-and-play financial widgets.

Complementary Tools for Armata Stock analysis

When running Armata Pharmaceuticals' price analysis, check to measure Armata Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Armata Pharmaceuticals is operating at the current time. Most of Armata Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Armata Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Armata Pharmaceuticals' price. Additionally, you may evaluate how the addition of Armata Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.

	Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk
	Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios.
	Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios
	CEOs Directory Screen CEOs from public companies around the world
	ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments
	Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk

Is Armata Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Armata Pharmaceuticals. If investors know Armata will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Armata Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(1.91)

Revenue Per Share

0.126

Quarterly Revenue Growth

0.454

Return On Assets

(0.26)

Return On Equity

(34.39)

The market value of Armata Pharmaceuticals is measured differently than its book value, which is the value of Armata that is recorded on the company's balance sheet. Investors also form their own opinion of Armata Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Armata Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Armata Pharmaceuticals' market value can be influenced by many factors that don't directly affect Armata Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Armata Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Armata Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Armata Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Armata Common Stock Total Equity vs Other Current Liab Analysis

Common Stock Total Equity vs Other Current Liab

Common Stock Total Equity vs Other Current Liab Correlation Analysis

Correlation Coefficient

Common Stock Total Equity

Other Current Liab

Armata Pharmaceuticals fundamental ratios Correlations

Armata Pharmaceuticals Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Armata Pharmaceuticals fundamental ratios Accounts

Pair Trading with Armata Pharmaceuticals

Moving against Armata Stock

Complementary Tools for Armata Stock analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Property Plant And Equipment Gross	+ 1.0	Property Plant And Equipment Net
Cash And Short Term Investments	+ 1.0	Cash
Common Stock	+ 1.0	Common Stock Total Equity
Non Current Assets Total	+ 0.99	Total Assets
Net Debt	+ 0.99	Short Long Term Debt Total
Total Liab	+ 0.99	Non Current Liabilities Total

Other Stockholder Equity	- 0.97	Retained Earnings
Common Stock	- 0.9	Short Term Investments
Short Term Investments	- 0.9	Common Stock Total Equity
Non Current Liabilities Total	- 0.76	Total Stockholder Equity
Non Currrent Assets Other	- 0.72	Other Current Assets
Common Stock	- 0.7	Other Stockholder Equity